Kyverna Therapeutics Files 8-K
Ticker: KYTX · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1994702
Sentiment: neutral
Topics: 8-k, regulatory-filing
TL;DR
Kyverna filed an 8-K on 7/15, likely a routine disclosure.
AI Summary
On July 15, 2024, Kyverna Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, with no specific financial figures or material events detailed in the provided text. The report confirms the company's identity and filing details.
Why It Matters
This 8-K filing indicates Kyverna Therapeutics is making a regulatory disclosure or reporting on other events, which could signal updates to investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material information that would indicate a high risk.
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant
- 0000950170-24-083570 (filing_id) — Accession Number
- July 15, 2024 (date) — Date of Report
- 5980 Horton St., STE 550 (address) — Principal Executive Offices
- Emeryville, California (location) — Principal Executive Offices City and State
- 94608 (zip_code) — Principal Executive Offices Zip Code
- (510) 925-2492 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Kyverna Therapeutics?
The filing is primarily for Regulation FD Disclosure and to report on Other Events, as indicated by the Item Information.
When was this 8-K report filed by Kyverna Therapeutics?
The report was filed on July 15, 2024.
What is Kyverna Therapeutics' principal executive office address?
The principal executive offices are located at 5980 Horton St., STE 550, Emeryville, California, 94608.
What is the Commission File Number for Kyverna Therapeutics?
The Commission File Number for Kyverna Therapeutics is 001-41947.
What is the SIC code and industry for Kyverna Therapeutics?
The Standard Industrial Classification (SIC) code is 2836 for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 562 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-07-15 16:11:21
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar
Filing Documents
- kytx-20240715.htm (8-K) — 43KB
- kytx-ex99_1.htm (EX-99.1) — 23KB
- 0000950170-24-083570.txt ( ) — 186KB
- kytx-20240715.xsd (EX-101.SCH) — 25KB
- kytx-20240715_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 15, 2024, Kyverna Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has granted Regenerative Medicine Advanced Therapeutic ("RMAT") designation for KYV-101 for the treatment of stiff-person syndrome ("SPS"). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. On July 15, 2024, the Company announced that the FDA granted RMAT designation for KYV-101 for the treatment of SPS.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 99.1 Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KYVERNA THERAPEUTICS, INC. Date: July 15, 2024 By: /s/ Peter Maag, Ph.D. Name: Peter Maag, Ph.D. Title: Chief Executive Officer